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ORIGINAL RESEARCH
Objectives: Endothelial dysfunction is frequently present in patients with systemic lupus
erythematosus and may increase their risk of premature coronary artery disease. In this pilot
study we have characterized the relationship between endothelial function, measures of disease
activity, and cardiovascular risk factors in patients with lupus.
Methods: Clinical characteristics and cardiovascular risk factors were evaluated in 20 patients
with lupus. Flow-mediated dilation of the brachial artery was measured using high resolution
ultrasound and the presence or absence of coronary calcification determined by electron-
beam computed tomography. The relationship between these variables and flow-mediated
dilation was determined using Spearman correlation coefficients (RHO) and Mann Whitney-
Wilcoxon tests.
Results: Twenty patients (17 female) median age (interquartile range) 42.5 (32.0–47.5) years
were studied. The median flow-mediated vasodilation was 3.6% (1.7%–7.7%). In patients
with coronary calcification (n = 6), flow-mediated dilation was 2.1% (–0.42%–3.6%) compared
with 4.0% (3.5%–8.3%) in those without (p = 0.12). There was no significant relationship
between flow-mediated dilation and markers of disease activity, duration of disease, and
cardiovascular risk factors. Lower flow-mediated dilation was associated with duration of
corticosteroid therapy (RHO = –0.44, p = 0.05).
Conclusions: In these preliminary results, endothelial dysfunction is associated with long-
term exposure to corticosteroids.
Keywords: flow-mediated dilation, endothelium, inflammation, atherosclerosis, systemic
lupus erythematosus
Introduction
Systemic lupus erythematosus affects mainly young women, a group usually free of
atherosclerosis. Epidemiological studies have shown a marked increase in the
prevalence of myocardial infarction in patients with lupus (Manzi et al 1997). We
(Asanuma et al 2003), and others (Roman et al 2003), have used noninvasive
techniques to show that atherosclerosis is more frequent and occurs at a younger age
in patients with lupus. However, in addition to these structural atherosclerotic changes,
the effects of lupus on functional vascular responses are of interest since endothelial
dysfunction may predispose to atherosclerosis, participate in its pathogenesis, and
predict prognosis (Gonzalez and Selwyn 2003; Davignon and Ganz 2004). Therefore,
strategies to identify the causes of endothelial dysfunction and to reverse it in
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populations with a high risk of coronary heart disease are
of interest (Gonzalez and Selwyn 2003).
There is evidence that systemic lupus erythematosus is
associated with endothelial dysfunction as determined by
impaired flow-mediated dilation of the brachial artery (Lima
et al 2002). This association has been reported to be
independent of traditional cardiovascular risk factors,
measures of disease activity, or drug therapy (El-Magadmi
et al 2004; Johnson et al 2004). However, these studies either
excluded patients with hypertension or hyperlipidemia,
dichotomized corticosteroid exposure, or did not include
novel cardiovascular risk factors such as homocysteine (Tam
et al 2003), or lipoprotein (a) (Lp(a)). Both are suggested to
play a role in the pathogenesis of vascular disease in patients
with lupus.
We conducted a pilot investigation to study the
relationship between endothelial function, measured as flow-
mediated dilation of the brachial artery, and clinical
characteristics, including novel cardiovascular risk factors,
and cumulative exposure to corticosteroids in patients with
lupus.
Methods
Twenty consecutive eligible patients older than 18 years of
age were enrolled. They met the classification criteria for
systemic lupus erythematosus; had duration of disease
longer than one year; with no known cardiovascular disease;
and were willing to undergo both electron beam computed
tomography (EBCT) and measurement of flow-mediated
dilation. These twenty patients were part of a larger cohort
study to determine the prevalence of coronary calcification
in lupus; details regarding their enrollment, clinical
characteristics, the collection of clinical data and
performance of laboratory tests, and EBCT have been
published (Asanuma et al 2003). Post-ischemic flow-
mediated dilation of the brachial artery, a noninvasive
technique to measure endothelium-dependent, nitric oxide
mediated responses in vivo (Corretti et al 2002) was
performed and analyzed as we have described elsewhere
(Dishy et al 2001). Flow-mediated dilation was expressed
as the percent change in diameter of the brachial artery
comparing resting and peak post-occlusion measurements.
Nitroglycerin (0.4 mg sublingual) was administered to
explore endothelium-independent dilation.
Spearman correlation coefficients were used to evaluate
the association between flow-mediated dilation and the
continuous variables. Mann Whitney-Wilcoxon tests were
used to compare the distribution of flow-mediated dilation
scores between different levels of categorical variables. No
corrections for multiple comparisons were performed
because we are presenting nonsignificant as well as
significant results (Senn 1997) in a setting where the goal
of data exploration was to generate hypotheses. All analyses
used a two-sided significance level of 5% and were
performed with the use of SAS software, version 8.02 (SAS
institute, Cary, NC, USA).
Results
The demographic characteristics and cardiovascular risk
factors for the twenty patients and their relationship to flow-
mediated dilation are shown in Tables 1 and 2. A longer
duration of corticosteroid use was associated with reduced
flow-mediated dilation (Spearman correlation coefficient
[RHO] = –0.44, p = 0.05). Although statistically non-
significant, directionally similar findings were found for current
Table 1 Characteristics of patients with systemic lupus
erythematosus
Categorical variables Number
Female sex 17 (85%)
White race  16 (80%)
Current smokers 6 (30%)
Hypertension  11 (55%)
Current use of hydroxychloroquine 12 (60%)
Current use of corticosteroids 16 (80%)
Current use of antihypertensives 11 (55%)
Current use of statins 3 (15%)
Postmenopausal status 5 (29%)
Presence of coronary calcium 6 (30%)
Age (years) 42.5 (32.0–47.5)
Body mass index (kg/m
2) 29.9 (26.8–33.1)
Systolic blood pressure (mm/Hg)  122.5 (114.0–141.0)
Diastolic blood pressure (mm/Hg) 80.5 (74.0–87.0)
Disease duration (years) 5.5 (4.0–11.0)
Pack years smoking  0 (0–14)
Framingham risk score  5 (1–9)
SLE disease activity index (SLEDAI) 3 (0–6)
SLE disease damage index (SLICC) 1 (0–1)
Total hemolytic complement 199.5 (175.0–288)
Erythrocyte sedimentation rate (mm/h)  25 (10–51)
C-Reactive protein (mg/dL)  0.4 (0.4–1.0)
High-density lipoprotein cholesterol (mg/dL)  42.5 (33.0–56.0)
Low-density lipoprotein cholesterol (mg/dL)  102.0 (77.0–136.0)
Triglycerides (mg/dL)  133.5 (73.5–156.5) 
Lipoprotein(a) (mg/dL)  30.0 (15.5–58.5)
Homocysteine (µmol/L)  9.2 (7.7–11.5)
Coronary calcium (Agatston units)  0 (0–17.6)
Corticosteroid duration (years)  5 (4–9.5)
Corticosteroid cumulative dose (g)  33.2 (8.9–74.8)
Values are median (interquartile range) or number (%).
Abbreviations: SLE, systemic lupus erythematosis.Vascular Health and Risk Management 2005:1(4) 359
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corticosteroid use (p = 0.11), cumulative corticosteroid dose
(p = 0.09), and maximum oral corticosteroid dose (p = 0.06).
Duration of corticosteroid use (RHO = –0.08, p = 0.73),
cumulative dose of corticosteroid (RHO = 0.12, p = 0.62),
current corticosteroid use (p = 0.33) and presence of
coronary-artery calcification (p = 0.25) were not significantly
associated with endothelium-independent, nitroglycerin
induced vasodilation.
Discussion
Our findings suggest that in this population of patients with
systemic lupus erythematosus with no known cardiovascular
disease, duration of corticosteroid therapy was significantly
associated with decreased flow-mediated dilation and that
cumulative and current corticosteroid use trended in the
same direction. In contrast, Lima et al (2002) found no
association between flow-mediated dilation and
corticosteroid use. A possible reason for this difference is
that Lima et al (2002) excluded patients with cardiovascular
risk factors such as smoking, hypertension, and hyper-
triglyceridemia. It is possible that the adverse effects of
corticosteroids on endothelial function may be more marked
in patients with cardiovascular risk factors. Given the result
of Spearman correlation coefficient analysis, 20% of the
variation in flow-mediated dilation is explained by
corticosteroid duration.
Age, disease duration, disease activity, and acute phase
reactants were not significantly associated with flow-
mediated dilation. There was no significant association
between flow-mediated dilation and any traditional or novel
cardiovascular risk factors, such as homocysteine and Lp(a).
However, these negative findings should be interpreted with
caution because they may be the result of lack of power to
detect significant associations due to the small number of
patients (n = 20). Thus, larger studies are required to confirm
our findings.
Glucocorticoids have been postulated as potential risk
factors for atherosclerosis in patients with lupus for several
years. (Urowitz and Gladman 1980) However, associations
between corticosteroids and osteoporotic fractures, cataracts
and coronary artery disease in these patients were more
apparent when cumulative prednisone was evaluated,
suggesting that time of exposure is an important determinant
of damage associated with corticosteroid use. (Zonana-
Nacach et al 2000). Previous studies of endothelial
dysfunction in lupus have either included exposure of
glucocorticoids as a dichotomous variable or have excluded
individuals with hypertension and hyperlipidemia (Lima et
al 2002; El-Magadmi et al 2004). This approach could have
biased the results, and made it more difficult to show an
association between glucocorticoids and endothelial
dysfunction.
In addition, there was a trend for patients with coronary-
artery atherosclerosis to have impaired flow-mediated
dilation, but the number of patients with calcification was
small and further studies to explore the relationship between
structural measure of vascular damage and endothelial
function will be of interest. The fact that none of the variables
associated with decreased flow-mediated dilation were
associated with decreased responses to nitroglycerin
Table 2 Relationship of patients’ characteristics and flow-
mediated dilation (FMD)
Categorical FMD (%) Median (IQR)
variables Present Absent p-values
Female sex 3.9 (1.8–8.3) 3.3 (–0.4–3.5) 0.15
White race 3.9 (1.3–8.8) 3.6 (3.5–3.9) 0.89
Current smokers 2.6 (1.0–3.7) 4.0 (3.3–8.3) 0.32
Hypertension 3.5 (1.8–4.5) 4.2 (1.0–9.4) 0.55
Current use of
hydroxychloroquine 3.6 (1.7–8.8) 3.7 (1.4–4.3) 0.57
Current use of
corticosteroids 3.5 (1.7–4.3) 10.9 (5.4–11.1) 0.11
Current use of
antihypertensives 3.6 (2.6–5.5) 3.9 (0.5–10.1) 0.91
Current use of statins 1.8 (–2.8–3.5) 3.9 (3.3–8.3) 0.13
Postmenopausal status 1.8 (1.0–3.7) 4.3 (3.5–8.8) 0.24
Coronary calcium 2.1 (–0.4–3.6) 4.0 (3.5–8.3) 0.12
Spearman
correlation
Continuous variables  coefficient p-values
Age (years) –0.08 0.74
Body mass index (kg/m2) 0.00 0.98
Systolic blood pressure (mm/Hg) –0.20 0.41
Diastolic blood pressure (mm/Hg) –0.34 0.14
Disease duration (years) –0.26 0.26
Pack years smoking –0.09 0.71
Framingham risk score –0.27 0.25
SLE disease activity index (SLEDAI) –0.05 0.85
SLE disease damage index (SLICC) –0.26 0.27
Total hemolytic complement (units) 0.11 0.65
Erythrocyte sedimentation rate (mm/h) –0.19 0.42
C-Reactive protein (mg/dL) 0.02 0.94
High-density lipoprotein cholesterol (mg/dL) –0.15 0.54
Low-density lipoprotein cholesterol (mg/dL) –0.14 0.55
Triglycerides (mg/dL) –0.20 0.41
Lipoprotein(a) (mg/dL) 0.04 0.86
Homocysteine (µmol/L) –0.27 0.26
Coronary calcium (Agatston units) –0.37 0.11
Corticosteroid duration (years) –0.44 0.05
Corticosteroid cumulative dose (g) –0.39 0.09
Corticosteroid maximum dose (g) –0.43 0.06
Abbreviations: IQR, interquartile range; SLE, systemic lupus erythematosis.Vascular Health and Risk Management 2005:1(4) 360
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suggests that the effects of corticosteroids may be on the
endothelium itself, rather than nonspecific structural effects.
This preliminary study has several limitations. First, the
power to estimate other significant associations is limited.
Second, longer glucocorticoid use could be a marker of more
severe disease over time. Third, the cross-sectional design
may not be sufficient to assess the contribution of variables
involving time such as disease activity over time. Fourth, as
a pilot study, the association between time of exposure to
corticosteroids and endothelial dysfunction is hypothesis-
generating rather than definitive. Further studies are required
to evaluate the role of disease severity and to evaluate the
association between cumulative corticosteroid exposure and
endothelial dysfunction that we have observed.
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